Purevax RC

RSS

vaccine against feline viral rhinotracheitis and feline calicivirosis

Authorised
This medicine is authorised for use in the European Union.

Overview

Purevax RC is a veterinary vaccine used to protect cats from the age of 8 weeks against feline viral rhinotracheitis (a flu-like illness caused by a herpesvirus) and feline calicivirosis (a flu-like illness with inflammation of the mouth caused by a calicivirus). The vaccine helps to reduce the symptoms of the diseases.

Purevax RC contains attenuated (weakened) feline rhinotracheitis herpesvirus (FHV F2 strain) and inactivated (killed) calicivirosis antigens (FCV 431 and G1 strains) as active substance.

This EPAR was last updated on 29/03/2022

Authorisation details

Product details
Name
Purevax RC
Agency product number
EMEA/V/C/000091
Active substance
  • attenuated feline rhinotracheitis herpesvirus (FHV F2 strain)
  • inactivated feline calicivirosis antigens (FCV 431 and G1 strains)
International non-proprietary name (INN) or common name
vaccine against feline viral rhinotracheitis and feline calicivirosis
Species
Cats
Anatomical therapeutic chemical veterinary (ATCvet) codes
QI06AH08
Publication details
Marketing-authorisation holder
Boehringer Ingelheim Vetmedica GmbH
Revision
16
Date of issue of marketing authorisation valid throughout the European Union
23/02/2005
Contact address

55216 Ingelheim am Rhein
Germany

Product information

17/02/2022 Purevax RC - EMEA/V/C/000091 - WS2201/0027

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Immunologicals for felidae

Therapeutic indication

Active immunisation of cats aged eight weeks and older:

  • against feline viral rhinotracheitis to reduce clinical signs;
  • against calicivirus infection to reduce clinical signs.

Onsets of immunity isone week after primary vaccination course.

The duration of immunity is one year after primary vaccination course and three years after the last re-vaccination.

Assessment history

How useful was this page?

Add your rating
Average
1 rating
2 ratings